Skip to NavigationSkip to content

Johnson & Johnson

J&J and Genmab’s drug races to second line treatment approval

Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been approved as a combination therapy for second-line treatment of bone marrow cancer. Janssen entered into a worldwide agreement to license and develop Darzalex back in 2012.

The drug Darzalex was trialled alongside Celgene’s Revlimid and Takeda’s Velcade, with the results being enough to convince the FDA to approve the combination therapy three months ahead of schedule.

GSK/J&J release how their drug measures up against Humira

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options for adults suffering from active rheumatoid arthritis, in comparison with market leader Humira. The trial evaluated the drug sirukumab, co-developed by the two companies, which is a human anti-interleukin (IL)-6 monoclonal antibody.

Janssen's Crohn's treatment licensed for UK use

Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European Commission for use in the UK as an option for moderate to severely active Crohn’s disease in adult patients who do not respond adequately to conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.

Collaboration on new therapeutic vaccine for HIV shows promise

Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into a new approach to combatting human immunodeficiency virus (HIV-1). The study was a collaboration between researchers at the Beth Israel Deaconess Medical Center (BIDMC), alongside scientists at Walter Reed Army Institute of Research (WRAIR), Janssen and Gilead Sciences.

BenevolentAI announces licensing agreement with Janssen

BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, of Johnson & Johnson. BenevolentAI will use their artificial intelligence technology, named the Judgement Augmented Cognition System, to provide their scientists with the tools to analyse vast amounts of scientific data.

Pfizer sets release date for rival to J&J’s blockbuster drug

Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. The drug will be only the second biosimilar available on the market and Pfizer have hopes to take a chunk out of Remicade’s sales of around $5 billion a year. Pfizer’s Inflectra will enter the market at a discount of 15% against Remicade.

AstraZeneca sells off third drug in five days

AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside the US. The deal, which will be completed for $330 million, sees Johnson & Johnson affiliate Cilag GmbH International gain the rights to sell the nasal spray outside of the US.

Patients' insulin pumps are revealed to be hackable by J&J

Johnson & Johnson have begun warning patients that their insulin pumps, that patients attach to their bodies and are controlled by wireless remote control, could potentially be hacked by enterprising hackers. It leaves open the possibility that the devices could be exploited to intentionally overdose diabetics with insulin.

J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial

Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque psoriasis than a placebo or AbbVie’s blockbuster drug, Humira. The data comes from a Phase III trial where 73 percent of patients who received the drug experienced near complete clearance compared with 2.9 of those who received a placebo and compared with Humira’s results of close to 50%. Statistically, the drug is far ahead of Humira.

Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as the ROCKET AF trial, that the blood testing device used to test an anti-clotting drug was not working correctly. The trial was for the blockbuster drug Xarelto (rivaroxaban), which was pitted in the trial against warfarin.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches